Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen.
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2015
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CHEER
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.